Neuspera Medical, Inc.

Neuspera Medical, Inc. is a medical device company specializing in advanced neurostimulation technology for the treatment of urinary urge incontinence (UUI), a symptom of overactive bladder (OAB) affecting approximately 1 in 5 women in the United States. The company's flagship product is the integrated Sacral Neuromodulation (iSNM) system, approved by the FDA in June 2025. The iSNM system represents a next-generation approach to sacral neuromodulation therapy, distinguished by its elimination of implanted batteries—a hallmark of traditional SNM devices. The system comprises a smart neurostimulator implanted near the sacral nerve and a discreet external battery worn daily that charges wirelessly, similar to smartphone charging technology. This design eliminates complications associated with implanted batteries while maintaining efficacy comparable to conventional SNM therapies. Neuspera positions its platform as advancing accessibility and patient comfort in UUI treatment. The company's technology foundation centers on directionally adaptive energy systems engineered to power medical implants. Clinical evidence supporting the iSNM system's safety and efficacy is available through Neuspera's published clinical study data. The device targets patients seeking effective UUI management with reduced cosmetic concerns and improved quality of life. Neuspera operates in the specialty urology medical device market, serving both patients and physicians as end-users and healthcare providers.